By a News Reporter-Staff News Editor at Biotech Week -- The New York State Department of Health (DOH) has granted Roswell Park Cancer Institute (RPCI) approval to begin genomic testing of cancer patients using its OmniSeq Target™ advanced molecular diagnostic laboratory test (see also Roswell Park Cancer Institute).
The test, approved through the DOH's Clinical Laboratory Evaluation Program (CLEP), is part of a comprehensive approach developed by the RPCI Center for Personalized Medicine for profiling and interpreting the genetic information contained in the tumor tissue of cancer patients. OmniSeq Target™ is one of only three tests approved for use in New York State that use next-generation sequencing, and it is the only assay to exclusively target actionable mutations -- those alterations for which targeted therapeutic approaches exist.
OmniSeq Target™ analyzes 23 different cancer-associated genes -- such as ALK, EGFR, PTEN, KRAS and NRAS. Using multiple high-throughput genomic technologies OmniSeq Target™ detects specific gene mutations, translocations and copy-number changes, looking for specific alterations and aberrations that indicate particular forms or targetable molecular characteristics of cancer. The test employs a dual sequencing platform for mutation testing, simultaneously using the Ion Torrent and Illumina sequencing platforms -- an approach that has unparalleled sensitivity and positive predictive value compared to the typical single-platform model.
"This is a next-generation cancer test that's both comprehensive and focused, and there's no other test like it on the market," says Carl Morrison, MD, DVM, Executive Director of the Center for Personalized Medicine. "That focus on actionable mutations is what makes our approach unique and what makes this test such an important tool in therapeutic decision-making. When a physician gets our test results back, they will be able to apply that new information and adjust a patient's treatment plan to get them on the appropriate targeted therapy."
Roswell Park Cancer Institute has also developed a software system that delivers clinically relevant information from OmniSeq Target™ testing into reports that become part of patients' electronic health records, enabling physicians to make more timely and informed treatment decisions. The comprehensive cancer center plans to incorporate OmniSeq Target(TM )testing into the care of many patients starting in the third quarter of 2014.
"This test represents a major step forward in patient care," says RPCI President & CEO Donald L. Trump, MD. "For years, the promise of genomic medicine has been largely theoretical and prospective. OmniSeq Target™ gives us the ability to identify, for many cancer patients, which therapy is going to be most effective for an individual, sparing patients from having to take a medication that was never going to work for them. We can expect dramatic improvements in both patient outcomes and quality of life."
The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email firstname.lastname@example.org. Follow Roswell Park on Facebook and Twitter.
SOURCE Roswell Park Cancer Institute
Keywords for this news article include: Genetics, Oncology, Personalized Medicine, Roswell Park Cancer Institute.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC